Market Size
The global nuclear medicine radioisotopes market was valued at USD 7.25 billion in 2025 and is estimated to reach USD 14.68 billion by 2033, growing at a CAGR of 7.6% during the forecast period from 2026 to 2033. The market is experiencing strong growth driven by the increasing prevalence of chronic diseases and the rising demand for advanced diagnostic and therapeutic solutions.
Medical radioisotopes are defined as safe radioactive substances that are primarily used to diagnose medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt since the rays can decay as soon as the imaging is completed.
Market Scope
| Metrics | Details |
| Market CAGR | 7.6% |
| Segments Covered | By Type of Radioisotopes, By Application, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Market Dynamics
The nuclear medicine radioisotopes market is primarily driven by the rising global burden of chronic diseases such as cancer, cardiovascular, and neurological disorders, which require advanced diagnostic and targeted therapeutic solutions. Increasing adoption of imaging modalities like PET and SPECT, along with the growing use of radiopharmaceuticals in oncology and cardiology, is significantly boosting demand for radioisotopes. Technological advancements, including the development of novel tracers and theranostic applications, are further enhancing clinical outcomes and expanding use cases. Additionally, rising healthcare expenditure, growing geriatric population, and increased investment in nuclear medicine infrastructure and R&D are accelerating market growth, particularly in emerging economies.
However, the market faces several restraints and challenges that can limit its expansion. The short half-life of radioisotopes creates significant logistical and supply chain complexities, requiring efficient production and rapid distribution systems. Limited global production capacity, dependence on aging nuclear reactors, and potential isotope shortages further disrupt supply continuity. High capital investment requirements, stringent regulatory frameworks, and safety concerns related to radioactive materials increase operational costs and delay market entry. In addition, reimbursement uncertainties, lack of skilled professionals, and competition from alternative imaging technologies such as MRI and CT scans can hinder adoption, especially in developing regions.
Recent Developments
February 2026: In North America, particularly the United States, increasing demand for advanced diagnostic imaging significantly accelerated the adoption of nuclear medicine radioisotopes, supported by strong investments in PET and SPECT technologies and expanding oncology applications.
January 2026: In Europe, countries such as Germany, France, and the United Kingdom witnessed growing production and supply chain optimization of medical isotopes, driven by government initiatives to reduce dependency on imports and strengthen regional isotope manufacturing capabilities.
December 2025: In Asia Pacific, especially China, India, and Japan, rising cancer prevalence and expanding healthcare infrastructure fueled demand for radioisotopes used in both diagnostics and targeted radionuclide therapies, making the region a key growth hub.
November 2025: In the Middle East & Africa, increasing investments in healthcare modernization and nuclear medicine facilities, particularly in the UAE and Saudi Arabia, supported gradual adoption of radioisotope-based diagnostic and therapeutic procedures.
October 2025: Globally, rapid advancements in targeted radiopharmaceuticals and theranostics significantly enhanced treatment precision, with growing focus on isotopes such as Lutetium-177 and Gallium-68 for personalized cancer care.
September 2025: Across global markets, supply constraints of key isotopes like Molybdenum-99 highlighted the need for alternative production methods, including cyclotron-based and non-reactor technologies, driving innovation in isotope generation and distribution.
The market is rapidly evolving toward precision diagnostics and targeted therapies, with strong momentum driven by rising cancer burden, increasing adoption of theranostics, and continuous advancements in radioisotope production technologies and nuclear medicine infrastructure worldwide.
Market Companies and Competitive Landscape
The global nuclear medicine radioisotopes market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include NTP Radioisotopes SOC Ltd, Nordion Inc., (Sotera Health company), Cardinal Health, Inc, Bayer AG, GE Company (GE Healthcare) and NorthStar Medical Radioisotopes, LLC.
Global Nuclear Medicine Radioisotopes Market – Key Companies to Watch
Cardinal Health, Inc
Overview: Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States. Its headquarters are in Dublin, Ohio and Dublin, Ireland.
Product Portfolio: It offers an extensive portfolio of PET radiopharmaceuticals dispensed from more than 100 nuclear pharmacies across the country. Some includes Fluorine F 18 flutemetamol (VIZAMYL), Fluorine F 18 fludeoxyglucose, Fluorine F 18 sodium fluoride, Gallium Ga 68 dotatate (Netspot), Nitrogen N 13 ammonia, Copper Cu 64 dotatate (Detectnet).
